ES2052579T3 - Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida. - Google Patents

Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida.

Info

Publication number
ES2052579T3
ES2052579T3 ES87309312T ES87309312T ES2052579T3 ES 2052579 T3 ES2052579 T3 ES 2052579T3 ES 87309312 T ES87309312 T ES 87309312T ES 87309312 T ES87309312 T ES 87309312T ES 2052579 T3 ES2052579 T3 ES 2052579T3
Authority
ES
Spain
Prior art keywords
human recombinant
manufacture
interferon alpha
medicinal product
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87309312T
Other languages
English (en)
Inventor
Judith Feinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25446188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2052579(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2052579T3 publication Critical patent/ES2052579T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A PACIENTES INFECTADOS CON EL VIRUS QUE PRODUCE SIDA, HTLV-III, SE ADMINISTRAN DOSIS ALTAS DE INTERFERON ALFA RECOMBINANTE, QUE SON SUFICIENTES PARA HACER A LOS PACIENTES AVIREMICOS. LAS ALTAS DOSIS PUEDEN OSCILAR DESDE APROXIMADAMENTE 5 A 75 MILLONES DE UNIDADES INTERNACIONALES DE INTERFERON (ALFA)-2, PREFERIBLEMENTE (ALFA)-2B RECOMBINANTE, POR DIA POR INYECCION. LOS PACIENTES SE PUEDEN MANTENER EN UN ESTADO AVIREMICO, MANTENIENDO UN REGIMEN DE DOSIS DE 10 A 35 MILLONES DE UNIDADES INTERNACIONALES APROSIMADAMENTE, EN DOSIS SENCILLAS, DE 3 A 7 DIAS POR SEMANA.
ES87309312T 1986-10-22 1987-10-21 Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida. Expired - Lifetime ES2052579T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92192286A 1986-10-22 1986-10-22

Publications (1)

Publication Number Publication Date
ES2052579T3 true ES2052579T3 (es) 1994-07-16

Family

ID=25446188

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87309312T Expired - Lifetime ES2052579T3 (es) 1986-10-22 1987-10-21 Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida.

Country Status (8)

Country Link
EP (1) EP0266940B1 (es)
JP (1) JPS63104929A (es)
AT (1) ATE83381T1 (es)
CA (1) CA1297788C (es)
DE (1) DE3783122T2 (es)
ES (1) ES2052579T3 (es)
GR (1) GR3006999T3 (es)
OA (1) OA08768A (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT99837A (pt) * 1990-12-21 1992-12-31 Schering Corp Processo para a preparacao de composicoes farmaceuticas contendo interferao alfa e metodo para administracao de interferao alfa por inalacao oral para tratar asma e doencas pulmonares proliferativas nao malignas
MX9307733A (es) * 1992-12-23 1994-06-30 Schering Corp Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo.
FR2713657B1 (fr) * 1993-12-13 1996-03-01 Transgene Sa Nouveaux vecteurs pour le traitement du sida.
BRPI0911444B8 (pt) 2008-04-28 2021-05-25 Janssen Pharmaceutica Nv benzoimidazóis como inibidores de prolil hidroxilase e composição farmacêutica que os compreende
EP3461820B1 (en) 2011-10-25 2020-07-29 Janssen Pharmaceutica NV Method for obtaining crystals of meglumine salt of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid

Also Published As

Publication number Publication date
CA1297788C (en) 1992-03-24
EP0266940B1 (en) 1992-12-16
ATE83381T1 (de) 1993-01-15
OA08768A (fr) 1989-03-31
DE3783122T2 (de) 1993-04-22
GR3006999T3 (es) 1993-06-30
DE3783122D1 (de) 1993-01-28
EP0266940A1 (en) 1988-05-11
JPS63104929A (ja) 1988-05-10

Similar Documents

Publication Publication Date Title
MX9302160A (es) Composiciones farmaceuticas del interferon de leu cocito humano concordante.
KR890700035A (ko) 개량된 인터페론 요법
IL87621A0 (en) Conjugates of cytokines with immunoglobulins,their preparation and pharmaceutical compositions containing them
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
DK602988D0 (da) Nukleosidderivater med antiviral virkning og laegemiddelpraeparat indeholdende saadanne forbindelser
PE72799A1 (es) Interferones polietilen glicol modificados
FI891774A0 (fi) Menetelmä lääkeaineen anto- ja/tai annostelumuodon valmistamiseksi
ES2052579T3 (es) Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida.
ES2051710T3 (es) Utilizacion de d-fenfluramina para la fabricacion de medicamentos para el tratamiento de depresiones.
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
FI954127A (fi) Menetelmä C-hepatiitin hoitamiseksi interferonihoitoon reagoimattomissa potilaissa
ES2058555T3 (es) Medicamento para el tratamiento intralesional del carcinoma de celulas escamosas, con alfa-interferon humano recombinante.
DK374388A (da) Immunterapeutisk, oral interferondosisform samt fremgangsmaade til fremstilling heraf
IT1284852B1 (it) Uso dell'interferone alfa naturale umano da cellule leucocitarie per la terapia delle epatiti virali, neoplasie e sindromi da
IT1283945B1 (it) Uso dell'interferone alfa naturale umano da cellule linfoblastoidi per la terapia delle epatiti virali, neoplasie e sindromi da
KR920014480A (ko) 기흉 치료용 제약 조성물을 제조하기 위한 인간 인터류킨 2의 활성을 갖는 폴리펩티드의 용도
TH29406B (th) องค์ประกอบสำหรับการบำบัดโรคตับอักเสบ บี
TH15782A (th) องค์ประกอบสำหรับการบำบัดโรคตับอักเสบ บี
TH33852A (th) การกระตุ้นกลไกป้องกันของโฮลท์ในการต่อต้านการประลองด้วยไวรัส
MY101495A (en) Treatment of diseases caused by viruses

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 266940

Country of ref document: ES